2024
Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial management
2023
Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy
Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology 2023, 83: 463-471. PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingSystematic biopsyProstate biopsyProstate biopsy procedureResonance imagingBiopsy coresTransrectal Ultrasound Guided Prostate BiopsyBiopsy procedureMultiparametric magnetic resonance imagingUnnecessary prostate biopsiesBiparametric magnetic resonance imagingOutpatient urology clinicNumber of biopsiesGuided Prostate BiopsyAcademic medical centerHealth care facilitiesEvidence-based approachUrology clinicClinical managementMedical CenterTriage strategiesClinical careTransrectal ultrasoundBiopsy
2021
An analysis of research biopsy core variability from over 5000 prospectively collected core samples
Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba I, Gupta S, Lee J, Overman M, Tam A. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. Npj Precision Oncology 2021, 5: 94. PMID: 34707215, PMCID: PMC8551285, DOI: 10.1038/s41698-021-00234-8.Peer-Reviewed Original ResearchAssociation between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.
Yang D, Dee E, Arega M, Nguyen P, Orio P, King M, Kann B, Yu J, Cook K, Ma T, Kishan A, Muralidhar V. Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2021.39.6_suppl.205.Peer-Reviewed Original ResearchPercentage of positive biopsy coresRisk of pelvic lymph node involvementPelvic lymph node involvementLymph node involvementPositive biopsy coresPelvic lymph nodesProstate cancerRadical prostatectomyBiopsy coresNode involvementLymph nodesDefinitive treatment of prostate cancerGleason 9-10 diseasePositive pelvic lymph nodesTreatment of prostate cancerBiopsy Gleason scoreClinicopathological prognostic variablesElective nodal irradiationGleason 8 diseasePathologic nodal evaluationClinical tumor stageNational Cancer DatabaseTime of RPClinically relevant associationMultivariate logistic regression
2020
Association Between Percentage of Positive Biopsy Cores and Risk of Pelvic Lymph Node Involvement in Prostate Cancer
Yang D, Dee E, Arega M, Nguyen P, Orio P, King M, Kann B, Yu J, Sandler K, Ma T, Kishan A, Muralidhar V. Association Between Percentage of Positive Biopsy Cores and Risk of Pelvic Lymph Node Involvement in Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e860. DOI: 10.1016/j.ijrobp.2020.07.427.Peer-Reviewed Original ResearchPharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
Motwani M, Modi D, Penugonda S, Zhang C, Palma J, Cunningham A, Calvo E, de Jonge M, LoRusso P. Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist. Journal Of Clinical Oncology 2020, 38: e15668-e15668. DOI: 10.1200/jco.2020.38.15_suppl.e15668.Peer-Reviewed Original ResearchPharmacodynamic effectsReceptor agonistMultiplex immunohistochemistryKRAS-mutant colorectal cancerTumor tissueDose-expansion cohortsSimilar time pointsMutant allele fractionM65 levelsH postdoseColorectal cancerPost-TxDownstream pathway activationPancreatic cancerHematologic malignanciesLiver enzymesScreening periodReverse phase protein arrayBiopsy coresTumor biopsiesMutant allele frequencyBiopsy samplesDose levelsBiopsyTumor types
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancerConservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
Mahal A, Butler S, Franco I, Pike L, Zhao S, Sanford N, Dess R, Feng F, D'Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Journal Of Clinical Oncology 2019, 37: 12-12. DOI: 10.1200/jco.2019.37.7_suppl.12.Peer-Reviewed Original ResearchLow-risk prostate cancerPositive biopsy coresProstate cancerShort-term outcomesBiopsy coresManagement of low-risk prostate cancerOlder patientsConservative managementMen ageActive surveillance/watchful waitingRate of conservative managementOlder menShort-term safetyDefinitive treatmentYounger patientsEnd ResultsOverall mortalityOptimal managementPatientsQuality of life implicationsNational databaseCancerMenAgeOutcomes
2018
How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?
Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyMulti-parametric MRILesion basisMRI-US fusion biopsyHistory of PCaHigh-grade cancerSignificant prostate cancerMRI-ultrasound fusion biopsyMpMRI studiesClinical suspicionPrimary outcomeSignificant PCaLesion biopsyDetection rateProstate cancerBiopsy coresBiopsyRegion of interestLesion targetingGenitourinary radiologistsCancerLesionsPatientsOne-quarterRole of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.
Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyProstate lesionsSignificant cancerProstate cancerSignificant cancer detection rateMRI-US fusion biopsyHigher PIRADS scoresHigh Gleason scoreSignificant prostate cancerMRI-ultrasound fusion biopsyProstate Imaging ReportingClinical suspicionGleason scorePIRADS scoreBiopsy histologyTemplate biopsyDetection rateLesion volumePathology gradeBiopsy coresMultiparametric MRILesion basisBiopsyImaging Reporting
2016
Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer
Dosoretz A, Yu J. Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer. Journal Of Clinical Oncology 2016, 34: 1718-1722. PMID: 27001587, DOI: 10.1200/jco.2015.66.3237.Peer-Reviewed Original ResearchConceptsExternal-beam radiotherapyDigital rectal examinationPalpable diseaseRectal examinationGleason 3+3 diseaseOncology Grand Rounds seriesHigh-grade prostate cancerMagnetic resonance imaging-ultrasound fusionMultiparametric magnetic resonance imagingAdjacent normal prostatePositive biopsy coresUltrasound-guided biopsyInguinal hernia repairT2-weighted imagesJournal of Clinical OncologyPatient's medical historyMagnetic resonance imagingHypointense featuresGleason 4Prostate volumePSA levelsAndrogen deprivationCataract surgeryIntraprostatic lesionsBiopsy cores
2014
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. Journal Of Cancer 2014, 5: 166-172. PMID: 24563671, PMCID: PMC3931264, DOI: 10.7150/jca.8167.Peer-Reviewed Original ResearchPD-L1 expressionMetastatic sitesPD-L1Tissue microarrayMetastatic specimensTumor PD-L1 expressionClear cell renal cell carcinomaPD-1 inhibitorsAutomated Quantitative AnalysisMetastatic RCC patientsCell renal cell carcinomaSite of metastasisRenal cell carcinomaClear cell RCCRenal cell carcinoma cellsInter-tumor heterogeneityRCC patientsCell carcinomaNephrectomy specimensTumor expressionCore biopsyImmune escapeCell RCCBiopsy coresClinical development
2013
Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer
Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal Of Korean Medical Science 2013, 28: 1796-1800. PMID: 24339711, PMCID: PMC3857377, DOI: 10.3346/jkms.2013.28.12.1796.Peer-Reviewed Original ResearchConceptsProstate-specific antigen densityTUR specimensElderly patientsPSA levelsGleason scoreProstate cancerBiopsy coresHigher prostate-specific antigen levelProstate-specific antigen levelElderly comorbid patientsRoutine prostate biopsySignificant co morbiditySpecific antigen densityHigh clinical suspicionSpecific antigen levelsProstatic needle biopsyPrebiopsy PSA levelProstate cancer diagnosisTUR specimenClinical suspicionCo morbiditiesPathologic reviewComorbid patientsTransurethral resectionAntigen levelsIncreased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance
Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkAA menRadical prostatectomyActive surveillanceProstate cancerNCCN criteriaBiopsy coresAS criteriaAS inclusion criteriaFinal surgical pathologyComprehensive Cancer NetworkPositive biopsy coresDatabase of menWorse clinicopathological featuresAfrican American menPathological upstagingAdvanced diseaseIndependent predictorsPathologic characteristicsClinicopathological featuresPreoperative PSAClinicopathologic findingsWA patientsInclusion criteriaPositive cores
1998
Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study
Naughton C, Smith D, Humphrey P, Catalona W, Keetch D. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998, 52: 808-813. PMID: 9801104, DOI: 10.1016/s0090-4295(98)00344-6.Peer-Reviewed Original ResearchConceptsProstate cancerBiopsy coresCore biopsySextant core biopsiesProstate volumeTotal prostate-specific antigen valuesProstate-specific antigen valuesMore biopsy coresMore biopsy sessionsPathologic tumor characteristicsPathologic tumor featuresSix-core biopsyTotal biopsy coresTRUS prostate volumeNegative prostate biopsyClinical prostate cancerMore biopsy samplesProstate cancer detectionPSA densityProspective trialInitial biopsyPathologic characteristicsProstatic volumeSerum tPSATumor characteristics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply